Compare GTEC & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTEC | SYBX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 15.2M |
| IPO Year | N/A | N/A |
| Metric | GTEC | SYBX |
|---|---|---|
| Price | $1.06 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 463.9K | 34.1K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $86,168,664.00 | N/A |
| Revenue This Year | $5.64 | N/A |
| Revenue Next Year | $3.93 | N/A |
| P/E Ratio | $0.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $0.90 |
| 52 Week High | $2.92 | $1.96 |
| Indicator | GTEC | SYBX |
|---|---|---|
| Relative Strength Index (RSI) | 58.42 | 47.80 |
| Support Level | $0.58 | $1.17 |
| Resistance Level | $1.15 | $1.27 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 80.73 | 61.11 |
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.